Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (USD $)	Total USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series B-1 12% redeemable convertible preferred stock Transaction 01 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Series C super dividend convertible preferred stock USD ($)	Series B redeemable convertible preferred stock USD ($)	Consultant USD ($)	Issuance During Period 1st USD ($)	Issuance During Period 1st Notes Payable USD ($)	Issuance During Period 1st Convertible Notes Payable USD ($)	Issuance During Period 1st Stock Options USD ($)	Issuance During Period 1st Series A 12% Convertible Preferred Stock Private Placement USD ($)	Issuance During Period 2nd USD ($)	Issuance During Period 2nd Convertible Notes Payable USD ($)	Issuance During Period 2nd Cash USD ($)	Issuance During Period 2nd Private Placement USD ($)	Issuance During Period 2nd Series B-1 12% redeemable convertible preferred stock USD ($)	Issuance During Period 3rd USD ($)	Issuance During Period 3rd Private Placement USD ($)	Issuance During Period 3rd Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Issuance During Period 4th Notes Payable USD ($)	Issuance During Period 4th Series C super dividend convertible preferred stock USD ($)	Issuance During Period 5th Private Placement USD ($)	Issuance During Period 6th Consulting Services USD ($)	Issuance During Period 7th Accrued Liabilities USD ($)	Issuance During Period 8th Private Placement USD ($)	Issuance During Period 9th Private Placement USD ($)	Issuance During Period 10th Private Placement USD ($)	Issuance During Period 11th Private Placement USD ($)	Issuance During Period 12th Cash USD ($)	Period 1 Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Issuance During Period 14th USD ($)	Issuance During Period 15th USD ($)	Series B-1 12% redeemable convertible preferred stock USD ($)	Series B-1 12% redeemable convertible preferred stock Transaction 01 USD ($)	Series B-1 12% redeemable convertible preferred stock Series B redeemable convertible preferred stock USD ($)	Series B-1 12% redeemable convertible preferred stock Issuance During Period 2nd USD ($)	Series B-2 12% redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock Transaction 02 USD ($)	Series B-2 12% redeemable convertible preferred stock Transaction 03 USD ($)	Series B-2 12% redeemable convertible preferred stock Series B redeemable convertible preferred stock USD ($)	Series B-2 12% redeemable convertible preferred stock Issuance During Period 3rd USD ($)	Series B-2 12% redeemable convertible preferred stock Period 1 USD ($)	Series C super dividend convertible preferred stock USD ($)	Series C super dividend convertible preferred stock USD ($)	Series C super dividend convertible preferred stock Issuance During Period 4th USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Common Stock USD ($)	Common Stock Series A 12% Convertible Preferred Stock	Common Stock Series B-1 12% redeemable convertible preferred stock	Common Stock Series B-2 12% Redeemable Convertible Preferred Stock	Common Stock Series C super dividend convertible preferred stock	Common Stock Consultant	Common Stock Issuance During Period 1st	Common Stock Issuance During Period 1st Notes Payable	Common Stock Issuance During Period 1st Stock Options	Common Stock Issuance During Period 2nd USD ($)	Common Stock Issuance During Period 2nd Cash	Common Stock Issuance During Period 3rd USD ($)	Common Stock Issuance During Period 3rd Private Placement USD ($)	Common Stock Issuance During Period 4th Notes Payable	Common Stock Issuance During Period 4th Series C super dividend convertible preferred stock	Common Stock Issuance During Period 5th Private Placement	Common Stock Issuance During Period 6th Consulting Services	Common Stock Issuance During Period 7th Accrued Liabilities	Common Stock Issuance During Period 8th Private Placement USD ($)	Common Stock Issuance During Period 9th Private Placement	Common Stock Issuance During Period 10th Private Placement	Common Stock Issuance During Period 11th Private Placement USD ($)	Common Stock Issuance During Period 12th Cash USD ($)	Common Stock Issuance During Period 14th USD ($)	Common Stock Issuance During Period 15th USD ($)	Additional Paid-in Capital USD ($)	Additional Paid-in Capital Series A 12% Convertible Preferred Stock USD ($)	Additional Paid-in Capital Series B-1 12% redeemable convertible preferred stock USD ($)	Additional Paid-in Capital Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-in Capital Series C super dividend convertible preferred stock USD ($)	Additional Paid-in Capital Consultant USD ($)	Additional Paid-in Capital Issuance During Period 1st USD ($)	Additional Paid-in Capital Issuance During Period 1st Notes Payable USD ($)	Additional Paid-in Capital Issuance During Period 1st Convertible Notes Payable USD ($)	Additional Paid-in Capital Issuance During Period 1st Stock Options USD ($)	Additional Paid-in Capital Issuance During Period 2nd USD ($)	Additional Paid-in Capital Issuance During Period 2nd Convertible Notes Payable USD ($)	Additional Paid-in Capital Issuance During Period 2nd Cash USD ($)	Additional Paid-in Capital Issuance During Period 2nd Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 2nd Series B-1 12% redeemable convertible preferred stock USD ($)	Additional Paid-in Capital Issuance During Period 3rd USD ($)	Additional Paid-in Capital Issuance During Period 3rd Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 3rd Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-in Capital Issuance During Period 4th Notes Payable USD ($)	Additional Paid-in Capital Issuance During Period 4th Series C super dividend convertible preferred stock USD ($)	Additional Paid-in Capital Issuance During Period 5th Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 6th Consulting Services USD ($)	Additional Paid-in Capital Issuance During Period 7th Accrued Liabilities USD ($)	Additional Paid-in Capital Issuance During Period 8th Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 9th Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 10th Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 11th Private Placement USD ($)	Additional Paid-in Capital Issuance During Period 12th Cash USD ($)	Additional Paid-in Capital Period 1 Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-in Capital Issuance During Period 14th USD ($)	Additional Paid-in Capital Issuance During Period 15th USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A 12% Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% redeemable convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% redeemable convertible preferred stock Transaction 01 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Deficit Accumulated During the Development Stage Series C super dividend convertible preferred stock USD ($)	Deficit Accumulated During the Development Stage Series B redeemable convertible preferred stock USD ($)
Beginning Balance at Jul. 10, 2000
Issuance of common stock upon exercise of warrants	$ 18,812,000																																																			$ 4,000																									$ 18,808,000
Issuance of common stock upon exercise of options																																																												2,772	611,945
Issuance of common stock upon exercise of options												74,000		632,000																																															1,000																									74,000	632,000
Issuance of common stock (in shares)																																																											99,705			31,000		537,227	17,647		181,334	2,042	33,618	399,917	219,096	206,019	333,334	1,250,000	2,666,722	599,942
Issuance of common stock	77,400,000									1,126,000						602,000				2,861,000		290,000		1,070,000	12,000	302,000	4,410,000	1,319,000	1,898,000	490,000	1,044,000		10,403,000	3,833,000																														1,000						1,000			1,000	1,000	3,000	1,000								1,126,000					602,000				2,860,000		290,000		1,070,000	12,000	302,000	4,409,000	1,319,000	1,898,000	489,000	1,043,000		10,400,000	3,832,000
Issuance of founders shares July 10, 2000 (in shares)																																																				2,059,112
Issuance of founders shares July 10, 2000	9,000																																																			2,000																									7,000
Accretion of redeemable convertible preferred stock			(1,320,000)	(2,215,000)	(685,000)																															1,320,000				2,215,000	685,000																																																																						(1,320,000)		(2,215,000)	(685,000)
Beneficial conversion feature	222,000																															1,016,000												(1,016,000)																																	222,000																												1,016,000
Issuance of common stock and beneficial conversion feature related to convertible note in 2001 (in shares)																																																				110,054
Issuance of common stock and beneficial conversion feature related to convertible note in 2001	1,036,000																																																																												1,036,000
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001 (in shares)																																																				203,649
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001	107,000																																																																												107,000
Issuance of Common Stock Warrants											503,000				236,000		261,000		20,000																																																																		503,000			236,000		261,000		20,000
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																																				114,884
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	2,221,000																																																																												2,221,000
Receipt of subscription receivable	150,000																																																																												150,000
Issuance of shares related to reverse split of common stock																																																				3,324
Modification of warrants																																																																													8,763,000																															(8,763,000)
Net loss	(84,080,000)																																																																																																											(84,080,000)
Reclassification of Warrant Liabilities	3,193,000																																																																												3,193,000
Convertible preferred stock dividend (in shares)																																																					185,392	334,913	653,274	86,967
Deferred compensation relating to issuance of stock options	455,000																																																																												455,000
Convertible preferred stock dividend		(47,000)				(33,000)																																																																								1,023,000	1,212,000	2,440,000	347,000																												(1,070,000)	(1,212,000)		(2,440,000)			(380,000)
Issuance of common stock upon exercise of warrants																																																				4,704,518
Stock compensation expense related to fair market revaluation	157,000																																																																												157,000
Issuance of redeemable convertible preferred stock													704,000					1,105,000			2,761,000																	395,000					1,174,000				2,203,000				704,000																																								1,105,000			2,761,000
Issuance of redeemable convertible preferred stock (in shares)																																						900,000					2,100,000				225				1,742,500
Stock compensation related to the issuance of common shares	53,000																																																																												53,000
Cumulative effect of adoption of new accounting principle	(204,000)																																																																												(458,000)																															254,000
Stock compensation related to the issuance of common shares (in shares)																																																				12,515
Issuance of restricted common stock (in shares)																																																				454,167
Issuance of restricted common stock																																																				1,000																									(1,000)
Stock-based compensation expense	15,424,000																																																																												15,424,000
Stock issued in conversion of convertible securities									1,745,000					3,948,000					5,330,000				284,000																								(284,000)		(117,000)												1,000		1,000															117,000					1,745,000				3,947,000					5,329,000				284,000
Stock issued in conversion of convertible securities (in shares)																																															(29)		(290,000)				48,387					79,367			1,227,972		867,558			48,527
Ending Balance at Dec. 31, 2013	1,481,000																																												1,919,000			587,000				18,000																									102,841,000																															(101,965,000)
Ending Balance (in shares) at Dec. 31, 2013																																													196			1,452,500				18,386,900
Beginning Balance at Dec. 31, 2011	(2,125,000)																																		1,681,000				2,687,000						2,154,000			632,000				13,000																									66,367,000																															(69,137,000)
Beginning Balance (in shares) at Dec. 31, 2011																																			900,000				2,100,000						220			1,562,500				12,919,538
Issuance of common stock upon exercise of options	51,830																																																			51,830
Issuance of common stock (in shares)																																																									11,348
Issuance of common stock								26,000																																																																										26,000
Accretion of redeemable convertible preferred stock							(174,000)																														17,000					157,000																																																																										(174,000)
Accretion of beneficial conversion feature for Series B-2	(56,000)																																						56,000																																																																					(56,000)
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																																				2,666,722
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	10,403,000																																																			3,000																									10,400,000
Issuance of shares related to reverse split of common stock																																																				3,324
Net loss	(9,675,000)																																																																																																											(9,675,000)
Convertible preferred stock dividend (in shares)																																																					31,250	95,584	223,027	46,053
Convertible preferred stock dividend																																																																														103,000	224,000	522,000	127,000																												(103,000)	(224,000)		(522,000)			(127,000)
Issuance of common stock upon exercise of warrants																																																				12,177
Stock-based compensation expense	2,766,000																																																																												2,766,000
Ending Balance at Dec. 31, 2012	1,165,000																																		1,698,000				2,900,000						2,154,000			632,000				16,000																									80,535,000																															(80,018,000)
Ending Balance (in shares) at Dec. 31, 2012																																			900,000				2,100,000						220			1,562,500				16,060,853
Issuance of common stock upon exercise of warrants	4,505,000																																																			1,000																									4,504,000
Issuance of common stock upon exercise of options	213,008																																																			213,008
Issuance of common stock upon exercise of options	271,000																																																																												271,000
Issuance of common stock (in shares)																																																				599,942
Issuance of common stock	3,833,000																																																			1,000																									3,832,000
Accretion of redeemable convertible preferred stock	(175,000)																																		17,000				158,000																																																																					(175,000)
Accretion of beneficial conversion feature for Series B-2	(54,000)																																						54,000																																																																					(54,000)
Issuance of Common Stock Warrants	(8,763,000)
Modification of warrants																																																																													8,763,000																															(8,763,000)
Net loss	(12,088,000)																																																																																																											(12,088,000)
Convertible preferred stock dividend (in shares)																																																					25,062	36,106	84,553	23,848
Convertible preferred stock dividend																																																																														148,000	178,000	418,000	123,000																												(148,000)	(178,000)		(418,000)			(123,000)
Issuance of redeemable convertible preferred stock						235,000																																								(235,000)				(45,000)																														45,000	235,000
Issuance of redeemable convertible preferred stock (in shares)																																														(24)				(110,000)					18,387	40,193
Stock-based compensation expense	3,789,000																																																																												3,789,000
Ending Balance at Dec. 31, 2013	$ 1,481,000																																		$ 1,715,000				$ 3,112,000						$ 1,919,000			$ 587,000				$ 18,000																									$ 102,841,000																															$ (101,965,000)
Ending Balance (in shares) at Dec. 31, 2013																																			900,000				2,100,000						196			1,452,500				18,386,900